Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000049936
- Lead Sponsor
- Graduate School of Medicine, Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method